<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814200</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076-106</org_study_id>
    <secondary_id>2018-004226-28</secondary_id>
    <nct_id>NCT03814200</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects</brief_title>
  <official_title>A Single-center, Randomized, Double-blind, Two-period Cross-over Study to Investigate the Effect of a Single Intravenous Dose of Rifampicin on the Pharmacokinetics of ACT-246475 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of rifampicin on the uptake and breakdown of ACT-246475
      in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Actual">February 19, 2019</completion_date>
  <primary_completion_date type="Actual">February 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t)</measure>
    <time_frame>Up to 36 hours after treatment administration</time_frame>
    <description>The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from zero to infinity (AUC0-inf)</measure>
    <time_frame>Up to 36 hours after treatment administration</time_frame>
    <description>The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 36 hours after treatment administration</time_frame>
    <description>The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time to reach Cmax (tmax)</measure>
    <time_frame>Up to 36 hours after treatment administration</time_frame>
    <description>The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (tÂ½)</measure>
    <time_frame>Up to 36 hours after treatment administration</time_frame>
    <description>The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Treatment period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A1: saline 0.9%
followed by
Treatment A2: ACT-246475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B1: rifampicin
followed by
Treatment B2: ACT-246475</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Single i.v. infusion of 100 mL saline 0.9% for 30 min</description>
    <arm_group_label>Treatment period A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-246475</intervention_name>
    <description>Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions</description>
    <arm_group_label>Treatment period A</arm_group_label>
    <arm_group_label>Treatment period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampicin</intervention_name>
    <description>Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min</description>
    <arm_group_label>Treatment period B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure

          -  Healthy male and female subjects aged between 18 and 65 years (inclusive) at Screening

          -  Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at Screening

          -  Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse
             rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine
             position at screening and on Day -1 of the first period

          -  Hematology and coagulation test results not deviating from the normal range to a
             clinically relevant extent at Screening and on Day -1 of the first period

          -  Women of childbearing potential must have a negative serum pregnancy test at Screening
             and a negative urine pregnancy test on Day- 1 of the first treatment period and must
             agree to consistently and correctly use a highly effective method of contraception

        Exclusion Criteria:

          -  Previous exposure to ACT-246475.

          -  Previous exposure to rifampicin within 3 months prior to Screening.

          -  Known hypersensitivity to P2Y12 receptor antagonists or rifampicin, or to any of the
             rifamycins, or any of their excipients

          -  Loss of 250 mL or more of blood within 3 months prior to Screening

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol

          -  Family or personal history of prolonged bleeding (e.g., after surgical intervention)
             or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial
             vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic
             ulcers

          -  Known platelet disorders (e.g., Glanzmann thromboasthenia, von Willebrand disease,
             platelet release defect)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

